These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 29908324)

  • 1. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
    Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
    Nakamura A; Kondo N; Nakamichi T; Kuroda A; Hashimoto M; Matsumoto S; Yokoi T; Kuribayashi K; Kijima T; Hasegawa S
    Jpn J Clin Oncol; 2020 Aug; 50(8):920-925. PubMed ID: 32463095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?
    Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P
    Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab for the treatment of unresectable pleural mesothelioma.
    Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
    Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
    [No Abstract]   [Full Text] [Related]  

  • 9. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.
    Fennell DA; Kirkpatrick E; Cozens K; Nye M; Lester J; Hanna G; Steele N; Szlosarek P; Danson S; Lord J; Ottensmeier C; Barnes D; Hill S; Kalevras M; Maishman T; Griffiths G
    Trials; 2018 Apr; 19(1):233. PubMed ID: 29669604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
    Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
    Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
    Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
    J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
    Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma.
    Yoneda H; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Ogino H; Otsuka K; Nishioka Y
    BMC Pulm Med; 2021 Nov; 21(1):373. PubMed ID: 34781910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
    Cerbone L; Delfanti S; Crivellari S; De Angelis AM; Mazzeo L; Proto C; Occhipinti M; Lo Russo G; Dellepiane C; Biello F; Alabiso I; Verderame F; Gauna R; De Simone I; Cuppone F; Petraglia S; Pasello G; Ceresoli GL; Garassino MC; Torri V; Grosso F
    Tumori; 2024 Jun; 110(3):168-173. PubMed ID: 38372045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Efficacy and Safety of Nivolumab: Results of a
    Okada M; Kijima T; Aoe K; Kato T; Fujimoto N; Nakagawa K; Takeda Y; Hida T; Kanai K; Imamura F; Oizumi S; Takahashi T; Takenoyama M; Tanaka H; Hirano J; Namba Y; Ohe Y
    Clin Cancer Res; 2019 Sep; 25(18):5485-5492. PubMed ID: 31164373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
    Nakamura A; Hashimoto M; Kondo N; Matsumoto S; Kuroda A; Minami T; Kitajima K; Kuribayashi K; Kijima T; Hasegawa S
    Int J Clin Oncol; 2023 Mar; 28(3):409-415. PubMed ID: 36609928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.